Several recombinant IFNβs have been approved for the treatment of multiple sclerosis (FDA, 2012), and there are few ongoing clinical trials utilizing IFNβ as an anti-cancer therapy (ClinicalTrials.Gov, 2012). Here, IFNB1 is linked to multiple sclerosis.